Real-world outcomes demonstrate sustained benefits of dupilumab in moderate-to-severe prurigo nodularis, indicating a robust treatment option.
Dupilumab provided sustained, clinically meaningful benefits and a favourable safety profile over 104 weeks, supporting its role as a long-term treatment for moderate-to-severe PN, including in elderly and comorbid patients.
No takes yet. Share an insight, caveat, or question.
Talamonti et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: